Author: Anoma Ranaweera B.V.Sc; PhD (Clinical Biochemistry, University of Liverpool, UK); Chief Editor: Dr Amanda Oakley, Dermatologist, Hamilton, New Zealand, June 2016. 


In March 2016, the US FDA approved Ixekizumab (TALTZ Eli Lilly, Indiana, USA) for the treatment of psoriasis. In November 2017, they also approved it for active psoriatic arthritis.

In April 2016, the European Medicines Agency also granted marketing authorization of ixekizumab for treatment of adults with moderate-to-severe plaque psoriasis who are candidates for systemic therapy.

Ixekizumab is a humanized immunoglobulin G subclass 4 (IgG4) monoclonal antibody (mAb) with neutralizing activity against IL-17A.  It  is produced by recombinant DNA technology in a mammalian cell line and  is comprised of two identical light chain polypeptides of 219 amino acids each and two identical heavy chain polypeptides of 445 amino acids each.

What is ixekizumab used for?

Ixekizumab is used for treating moderate to severe plaque psoriasis in adult patients thtat are candidates for systemic therapy (medicine absorbed into the blood stream) or phototherapy (ultraviolet light treatment). It has also been demonstrated to improve scalp psoriasis and nail psoriasis.

How does ixekizumab work?

 Dosage and administration

Link to key clinical-trial evidence about ixekizumab

Potential drug interactions with ixekizumab

What are the adverse effects of ixekizumab?

Ixekizumab is very well tolerated. Most common (≥1%) adverse reactions associated with ixekizumab treatment are:

Less common adverse reactions (<1%) include:

Warnings and precautions

Use of ixekizumab in pregnancy

Use of ixekizumab in nursing mothers

Paediatric use of ixekizumab

The safety and effectiveness of ixekizumab has not been established in paediatric patients (<18 years of age).

Geriatric use of ixekizumab

Clinical studies of ixekizumab did not include sufficient numbers of patients aged 65 years and older to determine whether they respond differently from younger patients.

Renal or hepatic impairment and ixekizumab

No formal studies have been conducted on the effect of hepatic or renal impairment on the pharmacokinetics of ixekizumab   

New Zealand approved datasheets are the official source of information for these prescription medicines, including approved uses and risk information. Check the individual New Zealand datasheet on the Medsafe website.

Related information

Email Newsletter

Would you like to receive our dermatology updates by email?


Submit your images

We're seeking high-quality photos of skin diseases.  


Machine diagnosis

Watch DermNet's proposal to create a 'Skin Disease Image Recognition Tool' - winner of the 2017 'Clinicians' Challenge Active Award' by the NZ Ministry of Health and HiNZ.

Subscribe to our mailing list

* indicates required
DermNet NZ Newsletter